Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 8/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6485236 | 1.00 | PDE4B (0.46) | PDE4BPDE4DPDE7BPDE4APDE4C | |
| Fumaric Acid SCHEMBL6485165 | 0.92 | PDE4D (0.51) | PDE4BPDE4DPDE7BPDE4APDE4C | |
| Fumaric Acid SCHEMBL6485152 | 0.92 | PDE4D (0.51) | PDE4BPDE4DPDE7BPDE4APDE4C | |
| SCHEMBL6485232 | 0.91 | PDE4D (0.44) | PDE4BPDE4DPDE7BPDE4APDE4C | |
| Fumaric Acid SCHEMBL6489086 | 0.86 | PDE4D (0.47) | PDE4BPDE4DPDE7BPDE4APDE4C | |
| Fumaric Acid SCHEMBL6489081 | 0.86 | PDE4D (0.47) | PDE4BPDE4DPDE7BPDE4APDE4C | |
| SCHEMBL6485752 | 0.85 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6485755 | 0.85 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6477013 | 0.85 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL6477017 | 0.85 | PDE4B (0.56) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | PDE4B 11/4885PDE4D 19/4885PDE7B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.